Terutroban is an
antiplatelet agent developed by
Servier Laboratories. It is a selective thromboxane prostanoid (TP) antagonist and is an orally active drug in clinical development for the secondary prevention of acute thrombotic complications.[1]
It has been tested in the
Phase III clinical trial PERFORM (Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack).[2] The study was prematurely stopped and it could not be determined whether terutroban has a better effect than
aspirin. The 2011 clinical trial that studied the antiplatelet agent versus aspirin found that it was not superior in the prevention of cerebral and cardiovascular ischaemic events, although it was significantly better in patients who already suffered previous stroke to the qualifying event.[3]
Researchers from the University of Milan also found in a new research that terutroban can prevent the development of aorta hyperplasia and has beneficial effects on fibrotic processes, leading to the conclusion that it has beneficial effects in preventing or retarding atherogenesis.[4]
^Hennerici MG, Bots ML, Ford I, Laurent S, Touboul PJ (2012). Stroke. Oxford, UK: Oxford University Press. p. 155.
ISBN9780199582808.
^Acton A (2012). Advances in Prostaglandins E Research and Application. Atlanta, GA: Scholarly Editions. p. 8.
ISBN9781481640084.
^Spreitzer H (January 29, 2007). "Neue Wirkstoffe - Terutroban". Österreichische Apothekerzeitung (in German) (3/2007): 116.
^Sorbera LA, Serradell, N, Bolos, J, Bayes, M (2006). "Terutroban sodium". Drugs of the Future. 31 (10): 867–873.
doi:
10.1358/dof.2006.031.10.1038241.